


Claims


1. Use of a combination of:

(a) a compound (A):



or a pharmaceutically acceptable solvate thereof; and

(b) a compound (B):



or a pharmaceutically acceptable solvate thereof,

in the manufacture of a medicament for treating cancer.


2. The use of claim 1, wherein the compounds of (a) and (b), or a pharmaceutically acceptable solvate thereof, are to be administered with: (c) an additional anti-cancer agent.

3. The use of claim 1 or 2, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, bladder cancer, colon cancer, uterine cancer, prostate cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.

4. The use of claim 2 or 3, wherein the cancer is hormone receptor positive (HR+) breast cancer and the additional anti-cancer agent is an endocrine therapeutic agent selected from the group consisting of an aromatase inhibitor, a selective estrogen receptor modulator (SERM) and a selective estrogen receptor degrader (SERD).

5. The use of claim 4, wherein the endocrine therapeutic agent is letrozole or fulvestrant.


6. The use of any one of claims 1 to 5, wherein the compound (A) is



7. The use of claim 6, wherein the amount of PF-07104091 is from 75 mg to 500 mg BID.


8. The use of claim 7, wherein the amount of PF-07104091 is 75 mg BID, 150 mg BID, or 225 mg BID.

9. The use of any one of claims 1 to 8, wherein the compound (B) is a hydrate of




10. The use of claim 9, wherein the amount of PF-07220060 is from 100 mg to 500 mg BID.
11. The use of claim 10, wherein the amount of PF-07220060 is 100 mg BID, 200 mg BID, or 300 mg BID.
12. The use of any one of claims 1 to 11, wherein the cancer is a palbociclib resistant cancer.
13. The use of any one of claims 1 to 11, wherein the subject has previously been treated with a CDK4/6 inhibitor.
14. The use of claim 13, wherein the CDK4/6 inhibitor is palbociclib.
15. A combination comprising:

(a) a compound (A):




or a pharmaceutically acceptable solvate thereof; and

(b) a compound (B):



or a pharmaceutically acceptable solvate thereof,
wherein the combination of (a) and (b) is effective in treating cancer.


16. The combination of claim 15, further comprising (c) an additional anti-cancer agent; wherein the combination of (a), (b) and (c) is effective in treating cancer.
17. The combination of claim 15 or 16, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, bladder cancer, colon cancer, uterine cancer, prostate cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.
18. The combination of claim 16 or 17, wherein the cancer is hormone receptor positive (HR+) breast cancer and the additional anti-cancer agent is an endocrine therapeutic agent selected from the group consisting of an aromatase inhibitor, a selective estrogen receptor modulator (SERM) and a selective estrogen receptor degrader (SERD).
19. The combination of claim 18, wherein the endocrine therapeutic agent is letrozole or fulvestrant.
20. The combination of any one of claims 15 to 19, wherein the compound (A) is



21. The combination of claim 20, wherein the amount of PF-07104091 is from 50 mg to 250 mg BID.

22. The combination of claim 21, wherein the amount of PF-07104091 is 75 mg BID, 150 mg BID, or 225 mg BID.

23. The combination of any one of claims 15 to 22, wherein the compound of Formula




(B) is a hydrate of (PF-07220060).

24. The combination of claim 23, wherein the amount of PF-07220060 is from 100 mg to 500 mg BID.

25. The combination of claim 24, wherein the amount of PF-07220060 is 100 mg BID, 200 mg BID, or 300 mg BID.


26. A combination comprising:

(a) a compound (A):



or a pharmaceutically acceptable solvate thereof; and

(b) a compound (B):



or a pharmaceutically acceptable solvate thereof,
for use in therapy.